-
Posted by
Two Blokes Jul 11 -
Filed in
Stock
-
8 views
Harrow's new 3-year share-based compensation plan sets ambitious share price targets, with awards at $50, $60, $75, and $100. The two previous plan targets were quickly surpassed, suggesting management is willing to set easily achievable SBC target prices. HROW acquired BYQLOVI for US distribution with minimal upfront cost, leveraging its proven distribution-focused business model to add another drug with $100M potential. Bloomberg reported stellar growth for HROW's most important drugs in Q2 2025, with growth coming in at 30% to more than 60% compared to Q1.
